Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celltrion’s Remicade Biosimilar Takes U.S. Regulatory Shortcuts

This article was originally published in PharmAsia News

Executive Summary

After just one year of working with the U.S FDA, the South Korean company is positioning itself to launch its first monoclonal antibody biosimilar in the U.S. market.

You may also be interested in...



FDA Expecting 10 Biosimilar Applications Submitted By End Of FY 2015

The agency says it expects to receive three biosimilar marketing applications in fiscal year 2014 and another seven in FY 2015, as well as much more in program revenue.

Sandoz’s Filgrastim Biosimilar Relies On Data Extrapolation

351(k) application seeks approval for full array of indications carried by Amgen’s Neupogen, which could give Sandoz product a competitive advantage over Teva’s marketed tbo-filgrastim, approved as traditional BLA.

Waiting For Biosimilars: From Manufacturing To Litigation, Stakeholders Prepare For U.S. Market

Leading players in the biosimilars realm discuss possible roadblocks to development, the battle over naming and substitution, and strategies to avoid the patent litigation dance.

Topics

Related Companies

UsernamePublicRestriction

Register

SC087857

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel